Comparative Pharmacology
Head-to-head clinical analysis: METHADOSE versus MORPHINE SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHADOSE versus MORPHINE SULFATE.
METHADOSE vs MORPHINE SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methadone is a mu-opioid receptor agonist; it also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake, contributing to its analgesic and detoxification effects. It has a long half-life and reduces opioid craving and withdrawal symptoms.
Agonist at mu, kappa, and delta opioid receptors in the central nervous system, mimicking endogenous endorphins. Primarily mu-receptor activation leads to analgesia by inhibiting adenylate cyclase, decreasing cAMP, and modulating ion channels (e.g., opening GIRK channels, closing voltage-gated calcium channels), reducing neurotransmitter release.
Oral: 20-40 mg once daily, titrated to effect; for opioid dependence, typical maintenance 80-120 mg/day. IV: 2.5-10 mg every 8-12 hours.
5-10 mg intravenously every 4 hours as needed; 10-30 mg orally every 4 hours as needed; 0.1-0.2 mg/kg intramuscularly every 4 hours as needed.
None Documented
None Documented
Terminal elimination half-life range: 8–59 hours (mean ~20–35 hours). In chronic use, half-life may increase due to accumulation. Context: The long half-life supports once-daily dosing for opioid dependence but requires careful titration to avoid accumulation.
Terminal elimination half-life: 2-4 hours in adults; prolonged in neonates (6-8 hours), elderly, and renal impairment (up to 15 hours).
Primarily renal (approximately 80%) as inactive metabolites, with about 20% eliminated via feces. Less than 10% excreted unchanged.
Renal: 90% (primarily as morphine-3-glucuronide and morphine-6-glucuronide, with 10% unchanged); Biliary/Fecal: 7-10%.
Category C
Category D/X
Opioid Agonist
Opioid Agonist